The company's restructuring plan should streamline it and increase cost efficiency. Amgen is also progressing with its pipeline, given quite a few regulatory and data updates scheduled for the coming quarters. Amgen also has several biosimilars in its pipelineincluding three oncology antibody biosimilar medicinesbeing developed in partnership with Allergan plc AGN.